41 results
Page 2 of 3
6-K
EX-1.1
soxnwe
26 Feb 20
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
4:15pm
424B5
jfsbkyjb4gob23u9
26 Feb 20
Prospectus supplement for primary offering
8:23am
20-F/A
3sn3fkovt5u9q37y
23 Jan 20
Annual report (foreign) (amended)
4:31pm
424B5
omd8x10
20 Nov 19
Prospectus supplement for primary offering
4:46pm
F-3
ykds3upo0h
7 Jun 19
Shelf registration (foreign)
3:31pm
6-K
EX-99.3
t0fwn
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.4
f6jhqm o8v48dvo03d
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.2
1kt9gf4s1malene
6 Dec 18
Amended Notice of Annual and Extraordinary General Meeting of the Shareholders
4:43pm
6-K
EX-99.2
wrvkfuw 4g8rixmw4o
19 Nov 18
Agreement and Plan of Merger
4:34pm
6-K
EX-99.1
ccmbvzwm5cdfwterdf7
19 Nov 18
Agreement and Plan of Merger
4:34pm
20-F
3z8w2c08jccjrl8ua jw
31 Mar 15
Annual report (foreign)
12:00am
424B4
1l0zuj7rbg3b9m5so
31 Jul 14
Prospectus supplement with pricing info
12:00am
CORRESP
olvd1vgb49j
28 Jul 14
Correspondence with SEC
12:00am